Related Experiment Video
Updated: May 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer
Nicolas Batty1, Naveen Yarlagadda, Roberto Pili
1From Department of Medicine, Roswell Park Cancer Center, Buffalo, New York.
Abstract:
Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclophosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.
Related Concept Videos
Treatment Resistant Cancers
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cushing Syndrome II: Pathophysiology
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

